Suggested remit: To appraise the clinical and cost effectiveness of blinatumomab with chemotherapy within its marketing authorisation for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commencing
ID number 6405

Project Team

Project lead

Email enquiries


Key events during the development of the guidance:

Date Update
24 April 2024 - 23 May 2024 Draft scope consultation: 6405
24 April 2024 In progress
21 February 2024 Topic selection